An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
CA 2407965 C · Owner: Kimberly, Robert P. · Inventors: Zhou, Tong; Koopman, William J.; Kimberly, Robert P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 2, 2001 and granted October 14, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 2, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 2, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.